Understood, thanks for the reply. In a normal "business as usual" scenario I would agree that if borderline, it's probably best to run things to the end for max credibility.
In this case however, I can't help but wonder if the double whammy of a stop for efficacy right on the heels would R-IT would provide a different kind of credibility at a time when the Co is surely fielding interest in the form of EU p-ships and who-knows-what in the US. Talk about making waves!
Of course, all of that depends on the business side having a say in the matter, and the inner workings of that are above my pay grade.
You mentioned (and I've read here from others) that "they" may have elected to push on in R-IT at 2nd interim when they didn't necessarily need to, but that visibility also goes against everything I thought I knew about the Co being insulated from the trial data until it concludes at the pre-determined end point or someone (??) says otherwise.
Thanks for your insight - admittedly out of my league here.
News 
Market Data 
Discover 
